Recombinant PDCD1 (Camrelizumab Biosimilar) antibody

Catalog No. ABIN7795091

This Humanized Monoclonal antibody specifically detects PDCD1 (Camrelizumab Biosimilar) in FACS and in vivo. It exhibits reactivity toward Human.

Quick Overview for Recombinant PDCD1 (Camrelizumab Biosimilar) antibody (ABIN7795091)

Target: PDCD1 (Camrelizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This PDCD1 (Camrelizumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-PDCD1 (Camrelizumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Camrelizumab Biosimilar, PD-1 Monoclonal Antibody

Characteristics: Camrelizumab Biosimilar uses the same protein sequences as the therapeutic antibody camrelizumab. Camrelizumab is an IgG4κ humanized monoclonal antibody being investigated for hepatocellular carcinoma. It targets programmed cell death protein 1 (PD-1), a protein on the surface of cells, also known as CD279 (cluster of differentiation 279). Camrelizumab is being evaluated in the Phase 2/3 (NCT02989922) of patients with advanced hepatocellular carcinoma (HCC) in second-line after failure or intolerance to prior systemic treatment. The study has 2 arms in which patients will be intravenous administered 3 mg/kg SHR-1210 on day 1 every 2 weeks or every 3 weeks. The primary outcome measures are the overall response rate (ORR) and overall survival (OS) rates at 6 months with duration of response and OS at 2 years as secondary endpoints. The estimated enrollment is 220 patients, and the estimated primary completion date is December 2018. A randomized, open-label Phase 3 study (NCT03099382) is evaluating the efficacy of camrelizumab treatment compared to standard-of-care treatment (docetaxel or irinotecan) in patients with esophageal carcinoma. Patients are randomly assigned to receive either SHR-1210 (200 mg every 2 weeks) or the standard of care (docetaxel 75 mg/m2 on day 1 every 3 weeks or irinotecan 180 mg/m2 on day 1 every 2 weeks). This Phase 3 study has an estimated enrollment of 438 and an estimated primary completion date of June 2018.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human PD1

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for PDCD1 (Camrelizumab Biosimilar)

Target: PDCD1 (Camrelizumab Biosimilar)

Alternative Name: Camrelizumab Biosimilar

Target Type: Biosimilar